Collectively, these results confirm the proposed mechanism of action for MTHFD2 inhibitors via induction of RS and provide rational support for the potential future use of MTHFD2 inhibitors as cancer-selective sensitizers to ATR-signaling blockade therapies. The gene discussed is ATR; the disease is cancer.